Transparency report in accordance with
- Medium-term financing secured through loan commitment
- Significant reduction of workforce
- Water filtration as core business area
The board of directors of Nanostart holding ItN Nanovation AG (ISIN DE000A0JL461) – which recently received a shareholder loan, thereby securing the medium-term financing of the company – today resolved to implement a comprehensive repositioning program. ItN Nanovation will place a stronger focus than previously on the promising growth area of water filtration. Emphasis will be on existing groundwater filtration and wastewater treatment activities. The repositioning program also reduces the workforce from 62 to 37 employees. A loan commitment from a large shareholder will provide a financial foundation for this more focused business alignment.
Nanostart AG (OTCQX: NASRY) headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government.
About ItN Nanovation:
ItN Nanovation AG (ISIN DE000A0JL461) is one of Germany’s leading nanotechnology companies. It develops innovative ceramic products such as filter systems and coatings for major industrial customers. The company manufactures the necessary nanoscale powder in-house. ItN Nanovation’s filter products can be used for drinking water treatment and wastewater purification, as filters in the drinks industry and to separate oil and water. Nanotechnology-based ceramic coatings are used as protective and catalytic layers in a wide range of applications in various industries, from ovens through aluminum foundries to coal-fired power stations. ItN Nanovation was founded in 2000. The company’s success is based on an extensive patent portfolio combined with in-depth development and application expertise. For more information on the company, please visit www.itn-nanovation.com.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
Dr. Hans Joachim D
Nanostart holding Lumiphore announced the European launch of three diagnostic tests by its partner ThermoFisher Scientific Clinical Diagnostics using Lumiphore’s time-resolved fluorescent reporter technology.
ThermoFisher Clinical Diagnostics has launched three CE-marked in vitro diagnostic tests in countries of the European Economic Area (EEA), consisting of the 27 Member States of the EU and EFTA countries, Iceland, Norway, Switzerland, and Liechtenstein.
The tests are assays produced by Brahms with the designations Copeptin us KRYPTOR, CT-proAVP KRYPTOR, and TRAK human KRYPTOR. Since June 2009, Brahms has been a contractual partner of Lumiphore. The company was acquired by ThermoFisher in September 2009.
These diagnostic tests use Lumiphore’s Lumi4